Kate Bowie , 2025-08-28 14:41:00
The first oral drug to treat moderate or severe postnatal depression has been approved in the UK.
The Medicines and Healthcare Products Regulatory Agency has said that zuranolone (Zurzuvae), manufactured by the US company Biogen, can be offered to mothers who develop the condition.1
Postnatal depression affects more than one in 10 women within a year of giving birth. Symptoms include persistent feelings of sadness or inadequacy, irritability, anxiety about …